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A B S T R A C T
In this study, a method is described to determine the monolayer loading capacity (MLC) of the drugs naproxen
and ibuprofen, both having high recrystallization tendencies, in mesoporous silica (MS), a well known carrier
that is able to stabilize the amorphous form of a drug. The stabilization has been suggested to be due to direct
absorption of the drug molecules onto the MS surface, i.e. the drug monolayer. In addition, drug that is not in
direct contact with MS surface can fill the pores up to its pore filling capacity (PFC) and is potentially stabilized
by confinement due to the pore size being smaller than a crystal nuclei. For drugs with high recrystallization
tendencies, any drug outside the pores crystallizes due to its poor physical stability. The drug monolayer does not
contribute to the glass transition temperature (Tg) in the DSC, however, the confined amorphous drug above MLC
has a Tg and the heat capacity (ΔCp) over the Tg increases with an increasing fraction of confined amorphous
drug. Hence, several drug loading values above the MLC were investigated towards the presence of a Tg and ΔCp
using differential scanning calorimetry (DSC). A linear correlation between the amount of confined amorphous
drug and its ΔCp was identified for the mixtures between the MLC and PFC. By subsequent extrapolation to zero
ΔCp the experimental MLC could be determined. Using theoretical density functional theory (DFT) and ab initio
Molecular Dynamics (AIMD), the binding energies for the monolayer suggested that the monolayer in fact is
thermodynamically more favorable than the crystalline form, whereas the confined amorphous form is ther-
modynamically less favorable. Consequently, a physical stability study showed that the confined amorphous
drugs above the MLC were thermodynamically unstable and consequently flowing out of the pores in order to
crystallize, whereas the monolayer remained physically stable.
1. Introduction
Amorphous formulations are one of the most efficient ways of im-
proving bioavailability in an era of drug discovery where a large per-
centage of new molecules have solubility-limited dissolution rates
(Riikonen et al., 2018; Sayed et al., 2018). In this context, mesoporous
silica (MS), having small pores (e.g., pore diameter between 2 and
50 nm) and large specific surface areas (e.g., often greater than 300m2/
g) (Andersson et al., 2004), have received quite some attention, due to
their ability to stabilize the amorphous form of a drug within their
mesopores (Kumar et al., 2014; Laitinen et al., 2013; Rouquerol et al.,
1994).
Inhibition of drug crystallization through adsorption to a MS has
generally been explained by two responsible mechanisms: i) molecular
interactions (e.g., hydrogen bonding) between functional groups of the
drug molecules and the surface of the MS, and ii) confinement and
spatial separation of the drug in the pores of MS, since the diameter of
the mesopores is smaller than a critical crystalline nuclei of the drug
(Azaïs et al., 2006; Rengarajan et al., 2008). With respect to i), the large
MS surface area provides additional surface free energy, and it has been
suggested that the adsorption of the drug in the amorphous form is
actually thermodynamically favorable because of the lower free energy
state than the crystalline drug (Andersson et al., 2004; Qian and
Bogner, 2011, 2012). When all binding sites on the MS surface are
occupied by drug molecules and an excess amount of drug is present in
the system, it cannot be in direct contact with the MS surface anymore,
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and it will start to form additional layers on top of the initial drug
monolayer (Genina et al., 2018; Hempel et al., 2018). In this case, the
drug will start filling up the pores and this excess amount of amorphous
drug may be stabilized by being physically restrained from crystal-
lization, in the case of ii). Thus, the surface area and pore volume of a
given MS influence the loading capacity of a given drug (Bavnhøj et al.,
2019; Yani et al., 2016).
Accordingly, the loading capacity of a drug in a MS can be differ-
entiated into two different classes, i.e. the drug in direct contact with
the MS surface forming a drug monolayer and any excess drug filling up
the pores. The former loading limit is dependent on the available sur-
face area of the MS and is referred to as monolayer loading capacity
(MLC). The latter is dependent on the pore volume of the MS and is
referred to as pore filling capacity (PFC). Any further addition of drug
will result in an overloading, i.e. drug being present outside of the pores
(Bavnhøj et al., 2019; Choudhari et al., 2014).
The MLC can be determined experimentally by a differential scan-
ning calorimetry (DSC) based method recently introduced by Hempel
et al. (2018). This method is based on deliberately overloading the MS
with the drug upon melting and quenching (using drug loadings of
50–90wt%), and subsequently determining the heat capacity change
(ΔCp) over the glass transition temperature (Tg) of the excess drug (i.e.
excess to the monolayer) upon reheating. Since the monolayer is not
contributing to the Tg signal in the DSC (Shen et al., 2010), the MLC can
be obtained by extrapolating the ΔCp values for the different drug
loading values to zero (x-intercept). Since the method relies on the
presence of an excess amorphous phase providing a Tg signal, it works
well for drugs with good or medium glass forming ability (GFA). Gen-
erally, drugs can be classified into three classes of GFA according to
their tendency to crystallize from the undercooled melt (Baird et al.,
2010), i.e. based on the presence/absence of observable crystallization
during a heat-cool-heat cycle using DSC. Briefly, class I drugs are
classified as poor glass formers and crystallize upon cooling of the melt,
class II are medium glass formers that do not crystallize upon cooling
from the melt but upon reheating above their Tg and class III are good
glass formers that neither crystallize upon cooling and reheating
(Avramov et al., 2003). In other words, the approach of Hempel et al.
(2018) is not feasible for drugs with poor GFA since these drugs would
crystallize outside the MS pores (at least above PFC), making a mean-
ingful determination of the ΔCp over the Tg of the excess drug at high
drug loadings above 50wt% not possible. On the other hand, it has
been suggested that at concentrations above the MLC but below the
PFC, the drug will be constrained within the pores and a crystallization
cannot occur within the pores due to the pore diameter being smaller
than a crystal nuclei (Qian and Bogner, 2012).
Consequently, the aim of this study was to investigate whether the
MLC of a class I drug with poor GFA, namely naproxen, can experi-
mentally be determined by extending the drug-MS ratios to lower drug
loading to cover the region between MLC and PFC. Furthermore, the
impact of different degrees of drug loading, i.e. monolayer, pore filling
and overfilling, on the physical stability of such a system was studied
and compared to ibuprofen, a drug with good GFA (class III). Lastly, the
impact of drug loading upon storage below and above the Tg was in-
vestigated, in particular with a focus on the amorphous (in)stability of
the confined drug above MLC but below PFC, both for poor and good
glass formers.
2. Methods and materials
2.1. Materials
Naproxen (NAP; Mw=230.26 g/mol, minimal projection area
34.77 Å2, maximal projection area 72.19 Å2, molecular density 1.081 g/
cm3) and ibuprofen (IBU; Mw=206.28 g/mol, minimal projection area
35.44 Å2, maximal projection area 64.57 Å2, molecular density 0.974 g/
cm3) were purchased from Fagron (Barsbüttel, Germany). Syloid® 72 FP
(SYL; average pore diameter 10 nm, pore volume 1.20 cm3/g, surface
area 350m2/g) was received as a generous gift from Grace GmbH
(Worms, Germany). All chemicals were used as received.
2.2. Experimental MLC determination
Based on a method proposed by Hempel et al. (2018), the MLC was
determined from physical mixtures of the crystalline drugs with SYL.
Physical mixtures of drug and SYL (15–100wt% drug for IBU and
10–100wt% drug for NAP) were prepared by weighing in a total of
200mg of the material followed by gentle mixing using a mortar and
pestle. The mixing procedure was repeated three times in order to en-
sure proper mixing before the powder was collected and stored in an
airtight container at room temperature until use. The thermal proper-
ties of the samples were analyzed using a Discovery DSC from TA In-
struments (New Castle, DE, USA). The physical mixtures of the IBU
samples (~5mg) and NAP samples (~14mg) were analyzed in Tzero
aluminum pans with a perforated lid under 50mL/min nitrogen gas
purge. The Tg (midpoint) and the heat capacity change over the glass
transition (ΔCp) were determined using the TA Instruments TRIOS
(version 4.1.1) software.
For the determination of the MLC of IBU in SYL, the physical mix-
tures were exposed to a heat-cool-heat cycle using standard DSC. The
physical mixtures were first annealed at ~5 °C above the melting point
(Tm) of the drug for 5min to ensure complete fusion of the drug into the
pores and then quench cooled at a ballistic rate (maximum cooling rate
of the instrument) to−80 °C. The samples were subsequently heated at
a rate of 20 °C/min to 30 °C above the Tm of the drug. Each experiment
was conducted in duplicate.
For the determination of the MLC of NAP in SYL, the physical
mixtures were exposed to a heat-cool-heat cycle using modulated DSC.
The physical mixtures were first annealed at ~5 °C above the Tm of the
drug for 5min to ensure complete fusion of the drug into the pores and
then cooled to −80 °C at 10 °C/min. Subsequently, a modulated tem-
perature DSC was used to determine the Tg and ΔCp (J/g °C) due to the
higher sensitivity compared to standard DSC. The samples were ana-
lyzed from −80 °C to 80 °C at a heating rate of 2 °C/min with an un-
derlying modulated temperature amplitude of 1.0 °C and a period of
50 s. The Tg and ΔCp were determined from the reversing heat flow
signal. Each experiment was conducted in duplicate.
The MLC was determined by a linear fitting of ΔCp as a function of
drug loading in the physical mixtures. For IBU and NAP, the linear
fitting was performed on the drug loadings from 30 to 100 (wt%) and
20–50 (wt%), respectively. The experimental MLC is then obtained
from the x-intercept of the trendline. Furthermore, the prediction in-
terval with the upper and lower limits based on a 95% confidence in-
terval were determined considering each replicate of ΔCp as individual
data point.
2.3. Theoretical determination of the MLC and PFC
The theoretical MLC and PFC were based on a previous publication
by Bavnhøj et al. (2019). Briefly, the theoretical MLC is based on the
minimum projected surface area of the drug molecules and was calcu-
lated from Eqs. (1) and (2):
=
∙
∙
MLC
A M
A Nw
MS w drug
drug A
( )
(1)
where AMS is the surface area of the respective MS (m2/g), Adrug is the
minimal or maximal projection (surface) area of the respective drug
(m2/molecule) estimated using MarvinSketch version 18.12 from Che-
mAxon (Budapest, Hungary), NA is the Avogadro constant
(6.022·1023 mol−1) and Mw(drug) is the molecular weight (g/mol) of the
respective drug. Eq. (1) calculates the MLC as wdrug/wMS (MLCw). The
theoretical MLC as wt% of the entire formulation, i.e. wdrug/
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(wdrug+wMS), was calculated using Eq. (2):
=
+
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w
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The theoretical PFC was calculated based on the amorphous/mo-
lecular densities of the drugs and pore volume of the MS, according to
the Eq. (3):
=
∙
+ ∙
∙PFC
V ρ
V ρ1
100%
MSpore drug
MSpore drug (3)
where VMS pore is the pore volume of the MS (cm3/g) and ρdrug is the
molecular density of the drug estimated using MarvinSketch version
18.12 from ChemAxon (Budapest, Hungary). The PFC includes the drug
in the monolayer as well as the excess drug confined by the pores.
2.4. Theoretical ab initio molecular dynamics (AIMD) and density
functional theory (DFT) simulations
The CP2k software package was used for all AIMD simulations,
which incorporated three-dimensional periodic boundary conditions
(Hutter et al., 2014; VandeVondele et al., 2005). With the AIMD
method, the atomic dynamics are allowed to evolve in time according
to Newton’s equations of motion (i.e. F=ma), with the distinction
between classical molecular dynamics being that the forces in AIMD are
recomputed using quantum-mechanical simulations at each discrete
timestep in the simulation. Thus, the AIMD technique enables the in-
clusion of temperature, providing a meaningful description of the
structures and dynamics of materials at a high-level of theoretical ac-
curacy. The simulations made use of the Perdew-Burke-Ernzerhof (PBE)
density functional (Perdew et al., 1996) coupled with the dispersion
correction of Grimme (Grimme-D3 (Grimme et al., 2010, 2011). The
electronic wavefunctions were represented using the double-zeta DZVP
basis set (VandeVondele and Hutter, 2007). Simulations were per-
formed within the canonical ensemble (NVT), with the temperature
maintained at 200 K using a Nose-Hoover chain thermostat (Martyna
et al., 1992; Nosé, 1984, 2002). The initial model involved loading the
porous void with drug molecules to a loading limit of 10% less than the
crystallographic density of the respective solids. The surface functio-
nalization was set to an average OH-distribution of approximately
4.5 OH nm−1 to be as similar to the physically used SYL surface as
possible. The CRYSTAL17 (Dovesi et al., 2018) software package was
used for static DFT simulations to represent a two-dimensional periodic
surface (periodic along the x and y axes corresponding to an infinite
surface slab) with a single API molecule in the simulation cell. In order
to match the AIMD simulations, parameters were kept as similar as
possible. The D3-corrected PBE functional was coupled with the def2-
SVP (Weigend and Ahlrichs, 2005) basis set for all atoms. Optimizations
were performed at an effective temperature of 0 K to extract the fun-
damentally stable binding geometry of the adsorbed molecules.
2.5. Physical stability study
Physical mixtures of drug and SYL (15–60wt% drug in 5 wt% in-
crements for IBU and 10–60wt% drug in 5 wt% increments for NAP)
were prepared as described above and subsequently molten in a UF55
oven from Memmert (Schwabach, Germany) at 5 °C above Tm of the
respective drug for 5min. Subsequently, the mixture was removed from
the oven, quench cooled to room temperature and gently mixed using a
mortar and pestle. The procedure was repeated once more to ensure
that the mixture was homogeneous and the solid-state characteristics of
the powder samples were then analyzed using an X’Pert Pro dif-
fractometer from PANalytical (Almelo, the Netherlands) using CuKα
radiation (λ=1.5406 Å) at 45 kV and 40mA. The freshly prepared
samples were analyzed directly after preparation and after storage for
4 weeks under ambient conditions and at−80 °C in a closed container.
Approximately 3mg of sample was placed on aluminum plates and
measured over the angular range of 5–30° 2θ at a scanning rate of 4°
2θ/min and resolution of 0.001° 2θ. Results were analyzed using the
X’Pert Data Viewer (version 1.2) software.
3. Results and discussion
As mentioned in the introduction, it has previously been shown that
a DSC based method can be used to determine the MLC of a drug with
medium and good GFA in MS (Hempel et al., 2018). IBU is such a good
glass former, however, NAP is a poor glass former and recrystallizes
quickly already in the quenching step during the DSC run (Baird et al.,
2010; Blaabjerg et al., 2017). Hence, any excess NAP outside of the
pores would crystallize, which makes a meaningful determination of
the ΔCp over the Tg of the excess drug at a high drug loading above
50wt% not possible. However, since the drug will be constrained
within the pores at concentrations above the MLC but below the PFC, a
crystallization can in theory not occur within the pores due to the pore
diameter being smaller than a crystal nuclei (Qian and Bogner, 2012).
For this purpose, we have extended the drug-MS ratios to lower a drug
loading to cover the region between MLC and PFC in this study, i.e.
15–100wt% for IBU and 10–100 wt% for NAP. It is suggested that such
an approach will potentially allow the determination of ΔCp values also
for compounds with poor GFA, such as NAP (at least for a drug loading
ranging between MLC and PFC), allowing for a determination of their
MLC. In this case, the confined drug (pore filling) above the MLC would
remain amorphous, resulting in a Tg and ΔCp signal in the DSC, while
the drug outside the MS pores would crystallize.
For IBU-SYL, the experimentally determined MLC at zero ΔCp (x-
intercept) was found to be 26.6 wt% with a prediction interval from
22.6 to 29.9 wt% (Fig. 1), which was supported by the absence of a Tg at
a drug load of 25 wt% or below, suggesting that all drug was present as
a monolayer for these drug loadings. The theoretical MLC based on
minimum and maximum projected surface area was calculated at 25.3
and 15.9 wt%, respectively. The close agreement of the experimental
MLC and the theoretical MLC based on minimum projected surface area
suggest that the IBU molecules adsorb densely to the MS surface, i.e.
occupying as little surface area as possible. The theoretical PFC was
calculated to be 53.9 wt%. Since IBU is a good glass former, the
amorphous fraction of the drug from the pore filling (between MLC and
PFC) and outside the pores (overfilling), both contribute to the ΔCp,
resulting in a linear increase in the ΔCp values over the entire sample set
above MLC.
For NAP-SYL, a ΔCp value may in theory only be obtained for the
Fig. 1. Experimentally obtained ΔCp (J/g °C) values over Tg as a function of IBU
(wt%) loaded on SYL as well as their linear extrapolation between 30 and
100 wt% in SYL, r2= 0.99. The 95% confidence interval is represented in the
dashed lines.
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amorphous drug fraction between MLC and PFC. In other words, it is
expected that a ΔCp value is detectable for any drug loading above MLC
and below PFC. For drug loadings above PFC, one would assume that
the pores are completely filled with drug and additionally excess drug
would be on the outside of the pores. Since NAP is a poor glass former,
the drug outside the pores should crystallize, however, the drug con-
strained inside the pores could be amorphous and should be detectable.
From Fig. 2, it can be seen that below 20wt% drug loading, no Tgs or
ΔCp values were obtained. For the samples with drug loadings between
20 and 60wt%, indeed ΔCp values could be identified and a linear in-
crease of ΔCp was obtained for the samples between 20 and 50wt%,
suggesting that amorphous NAP is indeed filling up the pores. When
using the ΔCp values for the samples between 20 and 50wt%, an ex-
perimental MLC at zero ΔCp (x-intercept) was determined at 20.6 wt%
with a prediction interval from 19.1 to 22.2 wt%. The theoretical MLC
based on the minimum and maximum projected surface area for NAP
were calculated as 27.8 and 15.6 wt%, respectively. Since the experi-
mental MLC lies in between these two theoretical MLC values, it is
suggested that the NAP molecules are occupying a larger surface area
on the MS surface than calculated from the minimal projected surface
area of NAP. Hence, in contrast to IBU, the NAP molecules do not ad-
sorb as densely to the MS surface.
Interestingly, the ΔCp decreases with increasing NAP load (55 and
60 wt%) and then disappears for samples with drug loadings> 70wt%,
suggesting that a part or all of the drug above MLC is crystallizing
during the timeframe of the heat-cool-heat cycle in the DSC. In other
words, this suggests that the excess drug (above MLC and below PFC)
must rather flow out of the pores and crystallize outside of the pores
than remaining confined within the pores. To understand this finding
one needs to consider that i) only the monolayer drug is thermo-
dynamically favorable compared to the crystalline drug (Qian and
Bogner, 2012), ii) the confined drug not in the monolayer is purely
prevented from crystallization by the pore size being smaller than a
crystal nuclei (Qian and Bogner, 2012) and iii) the crystalline form of
the drug is thermodynamically more stable than the pure amorphous
form (Qian and Bogner, 2011) also when confined within the pores
(above MLC and below PFC). The findings suggest that if there is a
possibility for the drug to crystallize (drug loading above PFC), it will
crystallize quickly and any drug confined in the pores will flow out of
the pores and also crystallize. One may think of the drug crystallizing
outside of the pores acting as seed for further crystal growth, dragging
the confined drug out of the pores since it would be able to change into
a thermodynamically more favorable form. This is further supported by
the low Tg of NAP, its poor GFA and its high, inherent tendency to
crystallize. For the samples with a drug loading of 70 wt% and above,
this effect becomes so pronounced that all of the confined drug (except
the monolayer drug) recrystallizes on the outside of the pores. For the
samples containing 55 and 60wt% drug, i.e. close to the PFC, this effect
is only partial, and some amorphous drug can remain within the pores
during the timeframe of the DSC run, hence, contributing to the Tg and
ΔCp signal in the DSC measurement.
In order to investigate the underlying energetics driving inter-
molecular drug-surface and amorphous drug-drug interactions, the
binding energies of the various phases of the drugs were determined
using solid-state DFT and AIMD simulations. For these simulations, two
distinct models were generated and used, the first was a physical re-
presentation of the studied systems, consisting of a MS model, which
was loaded with drug to a density (within the pore) of 10% less than the
crystallographic density of the respective drug molecules. The second
was a two-dimensional periodic simulation where a drug molecule was
fully docked to the surface and allowed to relax in order to strictly
determine the potential of the drug-monolayer binding interaction. The
results of the two analyses for the adsorbed drug were very similar; the
‘physical’ model yields a relative drug-monolayer binding energy
(compared to the crystalline drug binding energy) for IBU of
−32.93 kJ mol−1, while the drug-surface 2D model yields a value of
−31.98 kJ mol−1. The results of the 2D monolayer model are provided
in Table 1 for both of the studied materials.
In both cases, the energetics point to the previously observed effect
that the drug-monolayer interaction is more stable than in the corre-
sponding crystalline form. Moreover, a fully amorphous model yields
net positive relative binding energies for the two materials, in line with
experimental expectations of the instability of the amorphous form and
the preference for crystallization. The simulations accurately confirm
that monolayer adsorbed drugs are more stable than the corresponding
crystalline counterparts, and a structural investigation provides some
rationale for this effect. It is important to note that the binding energy is
Fig. 2. Experimentally obtained ΔCp (J/g °C) values over Tg as a function of
NAP (wt%) loaded on SYL as well as their linear extrapolation between 20 and
50 wt% in SYL, r2= 0.99. The 95% confidence interval is represented in the
dashed lines.
Table 1
Binding energies and relative binding energies (ΔE, compared to the crystalline binding energies) for NAP and IBU for the monolayer and amorphous phases of the
two materials calculated from DFT simulations. All energies are in units of kJ mol−1 molecule−1.
Naproxen Ibuprofen
Binding Energy ΔE Binding Energy ΔE
Crystal −235.28 – −136.61 –
Monolayer −307.90 −72.62 −169.54 −32.93
Amorphous −167.14 +68.14 −41.79 +94.82
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defined as
= − ++E E E E( )binding drug surface drug surface (4)
such that the binding energy is not directly related to either the in-
dividual structures of the surface or drug on its own. However, the lack
of a fully periodic and well-ordered crystalline structure indirectly
improves the binding energy of the drug-surface interaction by enabling
the drug molecules to adopt a conformation that maximizes each in-
dividual interaction while at the same time allowing for conformational
freedom to adopt a more optimal molecular structure. For example, in
the NAP system, the crystalline interactions are dominated by hydrogen
bonding interactions between the carboxyl groups, with some weak
London dispersion forces between the hydrophobic core of the mole-
cule, and the individual molecular conformations are relatively stained
in order to maximize and balance intermolecular interactions with the
conformational strain. However, in the NAP-SYL system, the lack of
well-defined order and the nature of the MS surface allows the NAP
conformation more freedom to adopt a favorable structure, with the
surface subsequently adapting its geometry to accommodate the NAP
molecules. For example, hydrogen bonding interactions are maximized
in the adsorbed system, including the carboxylic acid and ether groups
of NAP (Fig. 3), as there are more hydrogen bond donors on the MS
surface than what are present in crystalline NAP. Furthermore, non-
traditional interactions are present, for example weak C***H–O hy-
drogen bonds, which do not provide enough of an energetic stabiliza-
tion to be observed in crystalline NAP, and are readily present due to
the overabundance of hydrogen bond donors on the MS surface. Ad-
ditionally, the increased dispersion forces due to the highly polar sur-
face, and the more optimal binding geometry of the drugs all combine
to drive the binding of the drugs and increased stability of the drug-SYL
materials.
Finally, the simulations provide a rationale for the theoretical de-
termination of the MLC for NAP previously described. As described
above, the experimental MLC value for NAP falls in between the pre-
dicted values using the minimum and maximum projected surface areas
of the individual molecules. Since the projected surface areas of NAP in
these calculations do not account for how the molecules bind to the
surface, this observation is readily explained by investigating the
binding geometry of the drug molecules with respect to the surface
(Fig. 3). Due to the maximized hydrogen bonding of the NAP molecules
on the MS surface, the drug molecules are not oriented completely
orthogonal to the SYL surface, but are slightly rotated. Considering the
hydrogen bonding pattern of the NAP molecules, the DFT calculations
allow to project a minimum and maximum surface area of 51.33 Å2 and
65.37 Å2. These corrected values were used in Eqs. (1) and (2), and the
theoretical MLC based on the minimum and maximum projected sur-
face area for NAP are now 20.7 and 17.0 wt%, respectively. The close
agreement of the experimental MLC (20.6 wt%) to the corrected theo-
retical MLC based on minimum projected surface area suggest that the
NAP molecules indeed are fulfilling their maximum hydrogen bonding
possibilities and subsequently adsorb densely to the MS surface, i.e.
occupying as little surface area as possible.
In order to investigate the effect of drug loading on the physical
stability, drug-SYL systems were prepared with a drug loading between
15 and 60wt% for IBU and 10–60 wt% for NAP and analyzed using
XRPD directly after preparation and after 4 weeks of storage at −80 °C
(below the Tg of the drugs) or under ambient conditions (above the Tg of
the drugs). It was assumed that below the MLC, these systems would be
thermodynamically stable and between the MLC and PFC, they would
be sterically stabilized (physically stable) by the drug confinement.
Storing the samples below and above their respective Tg would poten-
tially further contribute to stabilization or destabilization of the con-
fined amorphous drug, since above the Tg, the drugs may possess en-
ough mobility to leak from the pores and crystallize on the outside of
the pores. The pure amorphous IBU and NAP are known to be highly
unstable and rapidly recrystallize after preparation, mainly because of
their very low Tg of −45 °C and 5 °C, respectively (Blaabjerg et al.,
2017).
The XRPD diffractograms for the freshly prepared IBU-SYL systems
showed that all drug loadings except 60 wt% were fully amorphous
systems (Fig. 4). This finding confirms that IBU was completely loaded
into the pores of SYL up to 55wt%. Since the theoretical PFC for IBU
was found to be 53.9 wt%, it was expected that some crystallinity was
observed for the 60 wt%, being above the PFC, and due to the poor
physical stability of the pure amorphous IBU. The experimental MLC
was 26.6 wt%, suggesting that samples with drug loadings ≤25wt%
are below the MLC and samples between 30 and 55wt% represent those
with pore filling. Upon storage, it was observed that the drug loadings
below the MLC remained amorphous regardless of the storage condi-
tions. However, for the samples between 30 and 55 wt% drug loading,
Bragg peaks characteristic of crystalline IBU could be identified de-
pending on the storage conditions. When storing the samples above the
Tg of IBU (ambient conditions), all samples above the MLC re-
crystallized, whereas when storing below its Tg (at −80 °C) only the
two samples close to the PFC, i.e. 50 and 55 (wt%), showed re-
crystallization (Fig. 4).
Fig. 3. Model of the NAP-SYL surface showing traditional hydrogen bonding
(green circles), and non-traditional C***H–O hydrogen bond formation (blue
circle).
Fig. 4. X-rays diffractograms of IBU/SYL systems with different drug loadings
freshly prepared (top diffractogram within a given drug loading XRPD set) and
stored for 4 weeks either at −80 °C (middle diffractogram within a given drug
loading XRPD set) or under ambient conditions (bottom diffractogram within a
given drug loading XRPD set).
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The XRPD patterns for the freshly prepared NAP-SYL systems show
that fully amorphous systems can be prepared up to 35wt% drug
loading (Fig. 5). This suggests that amorphous NAP-SYL systems can be
prepared above the experimental MLC (20.6 wt%) but not entirely up to
its PFC (56.5 wt%) as seen for IBU. Furthermore, given the linear in-
crease of the ΔCp up to a drug loading of 50 wt% in the DSC (see above),
one may have expected that it would be possible to prepare fully
amorphous samples also up to a drug loading of 50 wt%. However, the
findings indicate that at loadings above 35wt%, at least parts of the
confined drug leaked out of the pores and crystallized as suggested
above. Due to the longer experimental time frame from preparation to
XRPD analysis compared to the rather short heat-cool-heat cycle during
the DSC runs, this becomes now even more visible also for drug load-
ings further away from the PFC (i.e. the samples with 40 to 55wt%
drug). Upon storage, this phenomenon becomes even more pronounced,
since now all samples between MLC and PFC (25 to 55wt%) showed
recrystallization when stored above the Tg of NAP (ambient conditions)
(Fig. 5). Interestingly, also the sample with 20 wt% drug loading
showed some recrystallization when stored under ambient conditions,
suggesting that the MLC lies below 20wt%. This was unexpected since
the experimental MLC was 20.6 wt%, however, the 95% confidence
interval (19.1–22.2 wt%) indicates that the experimental MLC may in-
deed be below 20wt%. An MLC below 20wt% is also supported by the
finding that the storage time (4 weeks) did not cause recrystallization of
the 10 and 15 (wt%) NAP samples regardless of the storage conditions.
When stored below the Tg of NAP (at −80 °C), the samples were gen-
erally more stable as expected, however, the sample with a drug loading
of 35 wt% recrystallized (Fig. 5), indicating that a confinement of the
drug (loadings between MLC and PFC) can prolong stability below Tg
for some time but cannot prevent crystallization over time.
4. Conclusion
It was shown that the MLC can be experimentally determined for
drugs that are poor glass formers under the condition that the confined
drug above MLC and below PFC remains amorphous in the heat-cool-
heat cycle applied in the DSC run. Using solid-state DFT and AIMD si-
mulations, it was confirmed that the drug-monolayer binding energies
are more favorable than those found in the crystalline state of the drugs,
which was reflected in the physical stability of the samples below the
MLC regardless of being stored below or above the Tg of the drugs. On
the other hand, above the MLC and below the PFC, the confined
amorphous drugs are thermodynamically unstable and consequently
resulted in recrystallization during storage. Nevertheless, the confine-
ment of the amorphous drug prolonged its physical stability compared
to the pure amorphous drug, which in turn allowed the experimental
determination of the MLC of the poor glass former NAP.
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